Table 5.
Characteristics of patients with suspected ChILI who were excluded after adjudication from three centres.
| Age and sex | Cancer, liver metastasis prior CPI (Y/N) | CPI regime | Cycles prior liver injury | Pattern of liver injury | Received empirical steroids | Diagnosis, liver injury resolved (Y/N) | Clinical outcome at 12 months |
|---|---|---|---|---|---|---|---|
| 50 F | MM (Y) | Ipilimumab + nivolumab | 3 | Mixed | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 51 F | MM (Y) | Ipilimumab + nivolumab | 3 | Hepatocellular | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 66 M | MM (Y) | Ipilimumab | 2 | Cholestatic | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 76 F | MM (Y) | Ipilimumab | 2 | Mixed | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 37 M | MM (Y) | Ipilimumab | 3 | Cholestatic | Yes | Liver metastases causing biliary obstruction (N) | Died of disease progression |
| 55 F | MM (Y) | Ipilimumab | 1 | Hepatocellular | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 50 M | MM (Y) | Ipilimumab | 4 | Cholestatic | No | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 55 F | MM (Y) | Ipilimumab | 2 | Cholestatic | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 59 M | MM (Y) | Ipilimumab | 4 | Cholestatic | No | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 73 F | RCC (N) | Nivolumab | 14 | Cholestatic | No | DILI (Y) | Nivolumab was restarted with no elevation in liver enzymes |
| 75 M | MM (N) | Adjuvant pembrolizumab | 1 | Cholestatic | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 63 M | MM (N) | Adjuvant pembrolizumab | 1 | Mixed | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 75 F | MM (N) | Pembrolizumab | 9 | Cholestatic | Yes | Cholangitis/biliary obstruction (Y) | Pembrolizumab was restarted with no elevation in liver enzymes |
| 69 M | MM (Y) | Ipilimumab + nivolumab | 1 | Cholestatic | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 62 M | MM (Y) | Ipilimumab + nivolumab | 1 | Hepatocellular | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
| 76 F | MM (Y) | Ipilimumab + nivolumab | 1 | Mixed | Yes | Disease progression with widespread liver metastases (N) | Died of disease progression |
ChILI, checkpoint inhibitor-induced liver injury; CPI, checkpoint inhibitors; DILI, idiosyncratic drug-induced liver injury; F, female; M, male; MM, malignant melanoma; RCC, renal cell carcinoma.